



Correction: Wild-type and mutated IDH1/2 enzymes and therapy responses

Remco J. Molenaar^{1,2,3} · Jaroslaw P. Maciejewski³ · Johanna W. Wilmink² · Cornelis J. F. van Noorden¹

Published online: 23 August 2018

© The Author(s) 2018. This article is published with open access

Correction to: *Oncogene*; <https://doi.org/10.1038/s41388-017-0077-z>; published online 25 January 2018

The originally published version of this article contained an error in Fig. 2. On the IDH1/2 mutated arrow, it incorrectly read 'NADP⁺ →NADPH' instead of the correct 'NADPH →NADP⁺'. This has now been corrected in the PDF and HTML versions of the article. The authors wish to apologize for any inconvenience caused.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. If you remix, transform, or build upon this article or a part thereof, you must distribute your contributions under the same license as the original. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by-nc-sa/4.0/>.

✉ Remco J. Molenaar
r.j.molenaar@amc.nl

¹ Cancer Center Amsterdam, Department of Medical Biology, Academic Medical Center, Amsterdam, The Netherlands

² Cancer Center Amsterdam, Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands

³ Department of Translational Hematology and Oncology Research, Cleveland Clinic, Cleveland, OH, USA